Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas

Stopped early · Phase 2

Conditions studied: Squamous Cell Carcinoma

In brief

Open-label, multi-center, single-arm, Phase 2 study of oral selinexor in patients with SCC of the head and neck (HN-SCC; Cohort 1), lung (L-SCC; Cohort 2), or esophagus (E-SCC; Cohort 3) who have relapsed or have metastasis following chemotherapy.

Key facts

Study ID

NCT02213133

Run by

Karyopharm Therapeutics Inc

People needed

45

Starts

2014-09-22

Expected to finish

2015-12-10

Last updated by the study team

2023-01-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older
• confirmed SCC of the head and neck, lung, or esophagus
• 1 to 2 prior therapies
• measurable disease at screening and documented progression within the past 6 weeks

You may not qualify if…

• patients requiring total parenteral nutrition
• unstable cardiovascular function
• substantially impaired gastrointestinal function
• Symptomatic brain metastases
• another malignancy within 3 years except adequately treated in situ carcinoma of any type, basal or non-melanomatous skin cancer

Where it is running

• University of Colorado Cancer Center — Aurora, Colorado, United States
• Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
• Northwestern University — Evanston, Illinois, United States
• Tufts Medical Center — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute / Harvard University — Boston, Massachusetts, United States
• Metrowest Medical Center — Framingham, Massachusetts, United States
• Karmanos Cancer Institute — Detroit, Michigan, United States
• Washington University School of Medicine / Washington University in St. Louis — St Louis, Missouri, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States
• Icahn School of Medicine at Mount Sinai — New York, New York, United States
• Herbert Irving Comprehensive Cancer Center / Columbia University — New York, New York, United States
• Gabrail Cancer Center — Canton, Ohio, United States
• Oregon Health and Science University — Portland, Oregon, United States
• Sarah Cannon Research Institute - Tennessee Oncology — Nashville, Tennessee, United States
• Vanderbilt-Ingram Cancer Center / Vanderbilt University — Nashville, Tennessee, United States
• Mary Crowley Cancer Research Center / Texas Oncology — Dallas, Texas, United States
• University of Washington — Seattle, Washington, United States
• Princess Margaret Hospital — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.